The estimated Net Worth of Ronald Hunt is at least $2.23 Million dollars as of 6 August 2024. Mr. Hunt owns over 247,934 units of Harpoon Therapeutics stock worth over $2,096,717 and over the last 6 years he sold HARP stock worth over $0. In addition, he makes $135,890 as Chairman of the Board at Harpoon Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Mr. Hunt HARP stock SEC Form 4 insiders trading
Ronald has made over 11 trades of the Harpoon Therapeutics stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 247,934 units of HARP stock worth $5,704,961 on 6 August 2024.
The largest trade he's ever made was buying 1,543,500 units of Harpoon Therapeutics stock on 25 October 2023 worth over $35,515,935. On average, Ronald trades about 83,437 units every 68 days since 2018. As of 6 August 2024 he still owns at least 91,122 units of Harpoon Therapeutics stock.
You can see the complete history of Mr. Hunt stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Ronald Hunt biography
Ronald (Ron) M. Hunt serves as Chairman of the Board of the Company. Mr. Hunt co-founded and has served as a Managing Director of New Leaf Venture Partners, a venture capital fund focused on biopharmaceuticals and other healthcare technologies, since 2005. From 1998 to 2005, Mr. Hunt was a venture capital investor and became a partner at the Sprout Group, an institutional venture capital firm. Prior to Sprout, Mr. Hunt was a consultant with The Health Care Group (a division of the Interpublic Group), a strategy consulting firm and a consultant within the pharmaceutical industry practice at Coopers & Lybrand Consulting, a consulting firm. Prior to these consulting positions, Mr. Hunt held a number of roles in the sales and marketing divisions of Johnson & Johnson and SmithKline Beecham Pharmaceuticals, both pharmaceutical companies. Mr. Hunt currently serves on the board of public company Iterum Therapeutics (Nasdaq: ITRM) and has previously served as a director for Relypsa, Inc. (Nasdaq: RLYP), Neuronetics, Inc. (Nasdaq: STIM) and Durata Therapeutics, Inc. (Nasdaq: DRTX). Mr. Hunt holds a B.S. from Cornell University and an M.B.A. from The Wharton School at the University of Pennsylvania. Our Board believes that Mr. Hunt’s expertise and experience in the venture capital and pharmaceutical industry, and his educational background provide him with the qualifications and skills to serve on our Board.
What is the salary of Ronald Hunt?
As the Chairman of the Board of Harpoon Therapeutics, the total compensation of Ronald Hunt at Harpoon Therapeutics is $135,890. There are 8 executives at Harpoon Therapeutics getting paid more, with Gerald McMahon having the highest compensation of $1,793,260.
How old is Ronald Hunt?
Ronald Hunt is 54, he's been the Chairman of the Board of Harpoon Therapeutics since 2020. There are 7 older and 5 younger executives at Harpoon Therapeutics. The oldest executive at Harpoon Therapeutics, Inc. is Gerald McMahon, 65, who is the President, Chief Executive Officer, Director.
What's Ronald Hunt's mailing address?
Ronald's mailing address filed with the SEC is C/O ITERUM THERAPEUTICS PLC, FITZWILLIAM COURT, FL. 1, LEESON CLOSE, DUBLIN 2, L2, .
Insiders trading at Harpoon Therapeutics
Over the last 6 years, insiders at Harpoon Therapeutics have traded over $62,512,704 worth of Harpoon Therapeutics stock and bought 26,100,850 units worth $525,945,967 . The most active insiders traders include & Co., Inc.Merck Sharp & Do..., Ronald Hunt, and Bioscience Plc Arix Bioscie.... On average, Harpoon Therapeutics executives and independent directors trade stock every 26 days with the average trade being worth of $9,736,866. The most recent stock trade was executed by & Co., Inc.Merck Sharp & Do... on 11 March 2024, trading 21,397,205 units of HARP stock currently worth $492,135,715.
What does Harpoon Therapeutics do?
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
What does Harpoon Therapeutics's logo look like?
Complete history of Mr. Hunt stock trades at Iterum Therapeutics Plc, Neuronetics Inc, and Harpoon Therapeutics
Harpoon Therapeutics executives and stock owners
Harpoon Therapeutics executives and other stock owners filed with the SEC include:
-
Gerald McMahon,
President, Chief Executive Officer, Director -
Dr. Natalie R. Sacks M.D.,
Chief Medical Offer -
Holger Wesche,
Chief Scientific Officer -
Georgia L. Erbez,
Chief Financial Officer -
Georgia Erbez,
Chief Financial Officer -
Natalie Sacks,
Chief Medical Officer -
Mark Chin,
Independent Director -
Julia Eastland,
Independent Director -
Ronald Hunt,
Chairman of the Board -
Scott Myers,
Independent Director -
Jonathan Drachman,
Independent Director -
Joanne Viney,
Independent Director -
Andrew Robbins,
Independent Director -
Joseph Bailes,
Independent Director -
Karin Thacker,
Vice President - Regulatory Affairs and Quality Assurance -
Omer Siddiqui,
Vice President - Development Operations and Project Management -
Rachael Lester,
Vice President of Corporate Development -
Che-Leung Law,
Vice President - Translational Medicine -
Christopher Whitmore,
Vice President - Finance -
Susan Jones,
Senior Vice President, Product Development -
Dr. Holger Wesche Ph.D.,
Chief Scientific Officer -
Julie M. Eastland,
Pres, CEO & Director -
James B Bucher,
Chief Legal Officer -
Alan Colowick,
Director -
Bio Ventures 2014, L.P.Mpm ...,
-
Ansbert Oncology Impact Fun...,
-
Bio Ventures 2014, L.P.Mpm ...,
-
Patrick Baeuerle,
Director -
Bioscience Plc Arix Bioscie...,
-
Luke Evnin,
Director -
Oncology Impact Fund L.P.On...,
-
Leaf Ventures Iii, L.P.New ...,
-
Leaf Biopharma Opportunitie...,
-
Lauren P Silvernail,
-
Frank J Lanza,
Principal Fin. & Acctng Ofc. -
Luke Nathaniel Walker,
Chief Medical Officer -
& Co., Inc.Merck Sharp & Do...,